Forte Biosciences Celiac Disease Study (FB102-301)
U.S. Multi-Site
See if you may be eligible for a phase 2 celiac disease study currently enrolling. The FB102-301 study is a celiac disease clinical trial researching the effectiveness of the investigational drug FB102 at treating symptoms and intestinal damage when gluten is ingested.
Participants receive compensation for time and travel.
Requirements:
- 18 to 70 years of age
- Diagnosed with celiac disease at least 12 months prior (confirmed by biopsy and blood test)
- Have maintained a gluten-free diet for at least 12 months
Other study requirements will apply.